Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
"Consistent and significant real-world research is critical as GLP-1 drugs are a considerable driver of cost and utilization for our clients and employer groups." This data contributes to Prime's holistic management approach to GLP-1 therapy, which was first showcased with its award-winning Year-1 persistence and cost-of-care data in 2023, Year-2 persistence data in July 2024 and Year-2 cost-of-care data in October 2024
The primary end point was histologic improvement (reduction) in MASH with no worsening of fibrosis
The default mode network and recurrent depression: a neurobiological model of cognitive risk factors
The relationship between type 2 diabetes, NAFLD, and cardiovascular risk
US$ 27.07
US$ 29.13
US$ 20.18
US$ 22.54
US$ 29.62
US$ 26.63
US$ 23.78
US$ 23.57
US$ 29.72
